News FROM LAB282
updates ON THE PROGRESS oF LAB282
AND THE PROJECTS IT SUPPORTS
LAB282: two years of drug discovery impact
LAB282, a unique funding-expertise hybrid model to accelerate Oxford therapeutics out of the lab and into the wider world, launched two years ago this month. When it was conceived, LAB282 was a unique concept to accelerate therapeutics research emerging from Oxford...
LAB282 celebrates a year of impact in Oxford
The £13m drug discovery partnership between Oxford University, Oxford Sciences Innovation and Evotec supported 12 new projects in first year of operation. LAB282, the £13m drug discovery partnership between Oxford University, Oxford Sciences Innovation and Evotec, is...
“With LAB282 we are very, very successful…”
Werner Lanthaler, CEO of Evotec, interviewed by Labiotech during Biotech 2017. Full interview and article at https://labiotech.eu/evotec-werner-lanthaler-biotech/
LAB282 accelerates Oxford University’s life sciences with second round of awards
LAB282, the drug discovery partnership for Oxford University, has made its second round of awards to support promising life sciences ideas with market potential emerging from the University. LAB282 is providing critical early stage guidance and industry validation to...
Drugs from bugs tops list of LAB282‘s first round of grants
Oxford University and Evotec’s drug discovery partnership launched last year to quickly accelerate drugs to market begins making awards, backing projects targeting cardiovascular and infectious diseases. Launched last year as a partnership between the University,...
LAB282 – accelerating drug discovery at Oxford
Oxford University, Oxford University Innovation, Oxford Sciences Innovation and Evotec announce a new partnership to advance the development of next-generation medicines arising from Oxford research. Called ‘LAB282’, the partnership will provide a £13m fund, open now...